Profit margin of Supernus Pharmaceuticals, Inc.
Profit margin is calculated with the selling price (or revenue) taken as base times 100. It is the percentage of selling price that is turned into profit. Profit percentages are calculated to find the ratio of profit to cost of an investment. Profit margin is an indicator of a company's pricing strategies and how well it controls costs. Differences in competitive strategy and product mix cause the profit margin to vary among different companies. The profit margin is used mostly for internal comparisons. It is difficult to accurately compare the net profit ratio for different entities. Individual businesses' operating and financing arrangements vary so much that different entities are bound to have different levels of expenditure, so that comparison of one with another can have little meaning. A low profit margin indicates a low margin of safety: higher risk that a decline in sales will erase profits and result in a net loss, or a negative margin.
Supernus Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. It offers Oxtellar XR, an extended-release oxcarbazepine for use in the treatment of epilepsy; and Trokendi XR, an extended-release topiramate, which is used for the treatment of epilepsy. The company's product candidates comprise SPN-810, a molindone hydrochloride that is in Phase III clinical trial for the treatment of impulsive aggression in patients with attention deficit hyperactivity disorder (ADHD); and SPN-812, a viloxazine hydrochloride, which has completed Phase IIb trial that is used for the treatment of ADHD. It also develops SPN-809, a viloxazine hydrochloride, which is in Phase II ready clinical trial for the treatment of depression. The company markets its products through wholesalers and pharmaceutical distributors. Supernus Pharmaceuticals, Inc. was founded in 2005 and is based in Rockville, Maryland.
|TPRE Third Point Reinsurance Ltd.||NYSE > Finance > Property-Casualty Insurers||20.90%|
|TAP Molson Coors Brewing Company||NYSE > Consumer Non-Durables > Beverages (Production/Distribution)||20.93%|
|TAP-A Molson Coors Brewing Company||NYSE||20.93%|
|BOKF BOK Financial Corporation||NASDAQ > Finance > Major Banks||20.94%|
|BOKFL BOK Financial Corporation||NASDAQ > Finance > Major Banks||20.94%|
|CBF Capital Bank Financial Corp.||NASDAQ > Finance > Major Banks||20.94%|
|SUPN Supernus Pharmaceuticals, Inc.||NASDAQ > Health Care > Major Pharmaceuticals||20.98%|
|LVNTA Liberty Interactive Corporation||NASDAQ > Consumer Services > Catalog/Specialty Distribution||1,486.79%|
|RVT Royce Value Trust, Inc.||NYSE||1,550.35%|
|ASG Liberty All-Star Growth Fund, Inc.||NYSE > Finance > Closed-End Fund - Equity||2,321.85%|
|WMIH WMIH Corp.||NASDAQ > Finance > Finance: Consumer Services||2,450.53%|
|INVT Inventergy Global, Inc.||NASDAQ > Technology > Telecom Services - Domestic||2,494.79%|
|CNCE Concert Pharmaceuticals, Inc.||NASDAQ > Health Care > Major Pharmaceuticals||122,824.66%|